How to Value a De Novo Dental Practice Startup

Every few months a dentist calls me about selling a practice they started 18 months ago. Usually it's a life event — a spouse relocating, a health issue, or the brutal realization that running a startup practice is a different job than practicing dentistry. And almost every one of those calls ends the same way: the number they have in their head is nowhere near what the market will pay.

De novo dental practices — meaning scratch-start practices less than three years old — are the hardest asset in dentistry to value. The standard percentage-of-collections method breaks down, DSO buyers won't touch them, and most of the value is still locked in a ramp-up curve that hasn't played out yet. Here's how buyers actually think about these deals.

Why Standard Dental Valuation Methods Fail

For an established dental practice, the math is well understood. Private buyers pay 60-85% of annual collections, DSOs pay 5-12x EBITDA, and there's 40 years of precedent to support both. I walked through all of that in my main guide to dental practice valuation. None of that framework works cleanly for a startup.

The collections method assumes your trailing twelve months represent a stabilized run rate. A de novo practice in month 14 might be collecting $45K/month, but that number is a moving target — it was $22K six months ago and might be $65K six months from now. Which number does a buyer pay 70% of? The answer, in my experience, is usually the lowest defensible one.

The EBITDA method fails for a different reason: there usually isn't any EBITDA. Most de novo practices are cash-flow negative or barely break-even for the first 18-30 months while the owner services $400K-$600K of startup debt, pays fixed overhead on a half-empty schedule, and draws minimal compensation. A DSO buyer looking for $500K+ in EBITDA simply has nothing to buy.

The Dental Startup Ramp-Up Curve

Every buyer who has looked at a de novo practice has the same mental model of how collections should ramp. Understanding this curve is critical because it drives every number in the negotiation.

A well-located general dentistry startup in a decent suburban market typically follows this pattern: Year 1 collections of $300K-$450K, Year 2 of $600K-$800K, Year 3 of $850K-$1.1M, and stabilization around $1.1M-$1.4M in Year 4-5. Practices in oversaturated urban markets ramp slower. Practices in underserved rural markets with no other providers within 20 minutes sometimes ramp dramatically faster.

When a buyer evaluates your startup, they're not paying for where you are today — they're paying a discount to where the curve projects. If you're 14 months in at $550K annualized, the buyer runs the numbers assuming you'll hit $900K in Year 3 and $1.2M in Year 5, then discounts heavily for execution risk.

How Buyers Actually Price De Novo Practices

There are three common valuation approaches I see buyers use on startup dental practices, and they all produce lower numbers than sellers expect.

Asset value plus goodwill floor. The most common approach for practices under 18 months old. The buyer values your equipment, buildout, and leasehold improvements at 40-60% of original cost(because it's now used, not new), then adds a small goodwill premium of $25K-$75K for the active patient base. A practice that cost $550K to build out might sell for $275K-$350K. Brutal, but that's the market.

Discounted collections. For practices 18-36 months old that have established some momentum, buyers apply a steep discount to the collections-based method. Instead of 70% of TTM collections, they pay 40-55% — reflecting the execution risk and the fact that patient retention across a transition is weaker when the selling dentist has only been there briefly.

Debt assumption deals. The quietest part of the market. If you have $450K remaining on your practice loan and minimal equity, sometimes the best outcome is a buyer who assumes your debt, pays you $25K-$75K for your time and effort, and takes over. It feels like losing, but if your alternative is closing the doors and still owing the bank, it's a rational outcome.

When DSOs Will Actually Engage

I'll save you a lot of phone calls: Heartland Dental, Aspen Dental, Pacific Dental Services, Smile Brands, and the PE-backed platforms generally will not acquire a single-location startup under three years old. Their entire underwriting model depends on stabilized EBITDA, and you don't have it.

The narrow exception is when a de novo happens to sit in a geographic hole in a DSO's existing footprint — a zip code where they've been trying to plant a flag for two years. In that case, they might acquire your location primarily for the real estate position, not the cash flow. Even then, expect an offer in the asset-value-plus-small-premium range, not a true EBITDA multiple.

The more realistic "institutional" path for a startup is a local group practice that's expanding and wants to add a second or third location. These buyers can underwrite a ramp-up because they've lived it themselves. They still won't pay mature-practice multiples, but they'll engage when a DSO won't.

What Actually Moves the Number

If you're planning to sell a de novo within the next 12 months, three things change your outcome more than anything else.

Active patient count, not collections. Buyers of startup practices care about how many patients you've actually attracted, because that's the real proof the location works. A practice with 650 active patients and $550K in collections is worth more than a practice with 400 active patients and $620K in collections. The first shows a marketing engine that works; the second shows a few high-value cases that may not repeat.

A hygiene program that exists. Startups often skip building hygiene because the doctor fills the schedule with higher-production restorative work. Then when they try to sell, buyers see no recall base and assume the patient retention will be terrible. Even a part-time hygienist with a basic recall system running for 6+ months meaningfully changes how buyers view the practice.

Lease assignability. Half the startup leases I review have landlord consent clauses that effectively give the landlord a veto over any sale, or they have personal guarantees that don't release on assignment. Both destroy deal value. Get your attorney to review the lease before you list.

The Honest Advice

If you're 12-24 months into a de novo and thinking about selling, the most valuable thing I can tell you is this: the curve is worth more than the exit. Almost every de novo I've seen sold in Year 2 sold for less than the owner's total invested capital. Almost every de novo that pushed through to Year 4-5 and stabilized sold for multiples of that invested capital.

Selling during the ramp means you're paying the buyer for the risk you already took. If there's any way to bring in an associate, take time off, restructure debt, or find a partner to get through the stabilization period, that's almost always the better financial outcome. If you genuinely need to exit, price the practice to where the market actually is — not where you need it to be — and focus on a clean transition that minimizes patient attrition.

A startup sale isn't a failure. Overpricing one and watching it sit for 18 months while collections drift sideways is.